Embryonal tumors of the central nervous system represent a highly malignant tumor group of medulloblastoma (MB), atypical teratoid/rhabdoid tumor (AT/RT) and primitive neuroectodermal tumor that frequently afflict children. AT/RT is often misdiagnosed as MB/primitive neuroectodermal tumor but with higher recurrence and lower survival rates. Pathogenesis of AT/ RT is largely unknown. In this study, we report both the miRNome and transcriptome traits in AT/RT and MB by using small RNA sequencing and gene expression microarray analyses. Our findings demonstrate that the miR-221/222-encoded micro RNAs are abundantly expressed in AT/RT but not in MB, which contribute substantially to the malignancy of embryonal tumors. miR-221/222 targeted SUN2, a newly discovered tumor suppressor, directly to increase cell proliferation and tumor malignancy in vitro and in vivo. Immunohistochemistry against SUN2 in a tissue microarray of 33 AT/RT and 154 MB tumor specimens also detected less SUN2 protein in AT/RT. Collectively, this study uncovers a novel tumor suppressor, SUN2, plays a critical role in miR-221/222-mediated AT/RT malignancy as well as supports miR-221/222 and SUN2 represent new promising targets for more active therapies in AT/ RT. In addition, our miRNome and transcriptome data also provide a roadmap for further embryonal tumor research.
Introduction
Embryonal tumors are a heterogeneous group of malignant neoplasms (WHO grade IV), which encompass medulloblastoma (MB), atypical teratoid/rhabdoid tumor (AT/RT) and primitive neuroectodermal tumor (1) . AT/RT was first described by Rorke et al. in 1987 and later was recognized as a rare, highly aggressive entity of embryonal tumor that predominantly occurs in infants and young children with a peak incidence between birth and 3 years of age (2) (3) (4) . It accounts for around 2-3% of pediatric brain tumors and ~10% of central nervous system (CNS) tumors in infants (2, 5) . More than half of these cases arise in the posterior fossa, and they may also be found in other CNS areas (6) . Because of limited sampling and true heterogeneity, AT/RT is often misdiagnosed as MB, the largest group of embryonal tumors arose in the cerebellum, or primitive neuroectodermal tumor, a heterogeneous collection of non-cerebellar MB-like lesions (4, 7) . Although recent studies suggest the usage of tandem high-dose chemotherapy and autologous stem cell transplantation or intensive multimodality treatment can be beneficial for at least a subset of cases in time to progression and overall survival, unfortunately, the prognosis for AT/RT patients is still grim (8) (9) (10) . New therapeutic tactics are required. A better understanding of pediatric brain tumor biology will help to assist in developing less toxic therapies and to provide better markers for disease stratification.
The origin and pathogenesis of AT/RT still remain uncertain. Micro RNAs (miRNAs) are small RNAs of 18-24 nucleotides in length involving in the regulation of a variety of biological processes, including tumor malignancy (11) (12) (13) . miRNA expression patterns in pediatric brain tumors, including AT/RT, classical MB, ependymoma, pilocytic astrocytoma and glioblastoma multiforme, have been explored by Agilent microarrays containing 470 human miRNAs. It was found that pediatric brain tumors exhibit tumorspecific miRNA signatures and differential miRNA expression compared with normal brain (14) . miR-129, miR-142-5p and miR-25 were differentially expressed in every pediatric brain tumor type, but miR-221 and miR-629 were overexpressed in AT/RT (14) . Another study compared the expression of 365 human miRNAs among AT/ RT, MB and normal brain by Illumina microarrays, on the other hand, suggested upregulation of miR-221 and miR-222 in AT/RT (15) . miR-221 and miR-222 are two highly homologous miRNAs encoded from the same gene at chromosome Xp11.3. Although miR-221 and miR-222 may act as oncomiRs or tumor suppressor miRNAs in several different types of human tumors (16) , the roles of these two miRNAs and the influence of their upregulation in AT/ RT are still unclear. Also, miRNAs other than miR-221 and miR-222 may play roles in AT/RT.
Until now, over 2000 miRNAs have been identified in human cells, and many more miRNAs are continuously being identified by newly available technologies including small RNA sequencing (smRNASeq). High-throughput sequencing is able not only to reveal the expression profiles of known miRNAs but also to discover new miRNAs that have not been recorded. SmRNA-Seq also helps to identify miRNA isomers, point mutations, or polymorphisms in cancer tissues (17) . So far no smRNA-Seq work has been reported on AT/RT or other pediatric embryonal tumors.
In this study, we hypothesize that there are miRNAs, proteincoding genes and etiological pathways unique to AT/RT. To provide a better understanding of AT/RT, we carried out comprehensive analyses of miRNome and transcriptome features for two major types of embryonal tumors, AT/RT and MB, by smRNA-seq and gene expression microarrays. We identified and characterized differentially expressed miRNAs and mRNAs between AT/RT and MB. Also, we investigated the impact of key miRNAs and gene (miR-221/222 and SUN2) on embryonal tumors. Our data not only provide insights into the molecular mechanisms underlying AT/RT etiology but also unravel new clues for future therapeutic strategy.
) resuspended in 100 μl of fresh minimum essential medium were injected subcutaneously into the dorsal right or left flanks of 6-to 8-week-old NOD/SCID mice. Tumor sizes were measured with calipers and analytical balance, and tumor volumes were calculated according to the formula: (Length × Width × Height)/2. For intracranial implantation, 6-to 8-week-old NOD/SCID mice were anesthetized with an intraperitoneal injection of Avertin (Sigma-Aldrich) at a dose of 240 mg/kg and immobilized in a Cunningham Mouse/Neonatal Rat Adaptor stereotactic apparatus (Stoelting, Wood Dale, IL). A 5-mm skin incision was made and a burr hole was drilled into the skull, 2.5 mm lateral and 0.14 mm posterior to the bregma. Then, 2 × 10 5 Daoy cells in 2 μl of fresh minimum essential medium were injected at a depth of 3.5 mm from the dura. The burr hole was sealed with bone wax, and the incision was sutured.
Bioluminescent imaging
Fifteen minutes prior to in vivo imaging, mice were treated by intraperitoneal injection (150 mg/kg in phosphate-buffered saline) of the d-luciferin substrate (Promega). The isoflurane-anesthetized mice were placed onto warmed stage inside the light-tight camera box. The Xenogen in vivo imaging system (IVIS) 50 system was used to visualize tumors, and photon measurement was defined around the tumor area and quantified using Living Image software (Caliper Life Science SA, Villepinte, France).
Magnetic resonance imaging
Magnetic resonance imaging (MRI) was performed on formalin-fixed mouse brains using a 9.4-T NMR spectrometer (Bruker Biospin GmbH, Ettlingen, Germany) equipped with a micro gradient coil and a volume coil of 15 mm inner diameter. T2-weighted images (coronal, sagittal and axial) were produced using a Turbo spin echo sequence with a repetition time of 10 000 ms, a rare factor of 4, a first echo time of 30 ms, a echo time interval of 30 ms, an effective echo time of 60 ms, a field of view of 18 × 18 mm, a slice thickness of 0.25 mm, a bandwidth of 50 000 Hz, an acquisition matrix of 256 × 128 (zero filling to 256 × 256), and 8 averages. A total acquisition time for each view was 42 min 40 s. The tumor volume was calculated from the three-dimensional reconstruction of MR images using Avizo 6.3 software (VSG, Bordeaux, France).
Statistical analysis
Unless indicated otherwise, Student's t-test was used to assess the significance of mean differences. Differences were considered significant at a P value of 0.05 or less, two tailed.
Results

Clinical characterization of pediatric embryonal tumors
In our series of 1429 cases of primary pediatric CNS tumors collected during 1971-2010, 226 cases (15.8%) were embryonal tumors. Among them, 172 cases (12.0%) were MB, 37 cases (2.6%) were AT/RT and only 17 cases (1.2%) were primitive neuroectodermal tumor. Here, we devote this study to AT/RT and MB. The age and sex distributions of pediatric patients with AT/RT and MB are listed in Supplementary Table 2, available at Carcinogenesis Online. In general, AT/RT patients (3.9 years old) were younger than MB patients (7.0 years old). Males were more susceptible than females to embryonal tumors. The 2-year and 5-year survival rates and median survival time of AT/RT patients (40.5%, 35.1% and 18.2 months) were lower than those of MB patients (72.1%, 57.6% and 54.5 months). And AT/ RT patients had worse overall survival than MB ones in Kaplan-Meier estimator ( Figure 1A) .
To explore the difference in molecular composition between AT/ RT and MB and to uncover what makes AT/RT a more malignant one, available fresh-frozen tumor specimens from 11 AT/RT and 23 MB patients were used in this study (Supplementary Table 2, available at Carcinogenesis Online, the study group; details in Supplementary Table 3 , available at Carcinogenesis Online). In the reference series and the study group of AT/RT, the majorities were located in the cerebellum (75.7% and 90.9%) and were also found in other areas. All MB, both the reference series and the study group, were located in the cerebellum. No apparent differences in clinical parameters were observed between our reference series and study group of embryonal tumors.
Feature miRNAs associate with different embryonal tumors
Global miRNA expression patterns of 4 AT/RTs and 4 MBs (including 2 classic, 1 desmoplastic and 1 anaplastic MBs) were first deciphered by smRNA-Seq and analyzed by our in-house bioinformatics pipelines ( Figure 1B ). These pipelines were conducted to process mRNA contamination, known miRNA filtering and format conversion. As additional filtering steps, sequences that were not annotated in any public database and were pinpointed by miRDeep2 or mireap algorithm were considered to be novel miRNA candidates (designated as UNI-X, in which X is numbered). The RPKM (reads per kilobase of exon model per million mapped reads) value for each miRNA was calculated to score its expression abundance. There are 147 known and 78 novel miRNAs expressed differentially between AT/RT and MB (P < 0.05). Multidimensional scaling (MDS) analysis based on the expression of these miRNAs showed a good discrimination between AT/RT and MB, suggesting AT/RT and MB have their own miRNome traits ( Figure 1C) . The all and top 50 differentially expressed known miRNAs are listed in Supplementary Table 4 and Supplementary  Figure 1 , available at Carcinogenesis Online, respectively.
Further analysis revealed that six and two miRNAs were selectively enriched in AT/RT and MB, respectively (q < 0.05; ≥15× fold change and ≥1000 RPKM in either group; Figure 1D ). The expressions of miR-448 (≥1000 RPKM; Figure 1D ) and a novel UNI-55-3p (≥100 RPKM; Figure 1K ) were also upregulated in AT/RT but could not be assigned a fold change because there were no detectable corresponding reads in MB smRNA-Seq data. Evidences in confirmation of the differential expressions of miR-222-3p, miR-221-3p, miR-221-5p, miR-448, miR-340-5p, miR-9-3p and UNI55-3p were obtained by RT-qPCR ( Figure 1E-K) , which corroborating the quantitative sequencing results.
Functional module analysis as a framework to interpret AT/RT and MB biology
Global mRNA expression profiles of 7 AT/RTs and 20 MBs were analyzed next. The MDS plot ( Figure 2A ) and gene expression heat map ( Figure 2B ) based on genes differentially expressed between each tumor type showed clearly that AT/RT and MB have their unique transcriptome characteristics. A total of 1428 probe sets (968 genes) were abundant in AT/RT, whereas another 699 (440) in MB (q < 0.0001; Figure 2B and Supplementary Table 5 , available at Carcinogenesis Online). Array data of selected genes were verified by RT-qPCR. AT/RT overexpressed cyclin D1 (CCND1; Figure 2C ), a key regulator of cell cycle G1/S transition which frequently to be mutated, amplified and overexpressed in a variety of tumors (18) (19) (20) . AT/RT overexpressed NOTCH2 ( Figure 2D ), which is involved in promoting tumor malignancy, metastasis and chemoradioresistance (21) . Also enriched in AT/RT was the dual-specificity phosphatase DUSP6 ( Figure 2E ), a critical regulator of extracellular signal-regulated kinase signaling cascade (22) . Interestingly, DUSP6
T.-H.Hsieh et al. has been implicated as a tumor suppressor in pancreatic cancer, nonsmall-cell lung cancers, esophageal squamous cell carcinoma and nasopharyngeal carcinoma, whereas it exerts oppositely a tumor-promoting role in human glioblastomas, one of the worst types of brain tumors (23) (24) (25) (26) . Other differentially expressed genes observed in microarray analysis, for example, overexpression of TPP1 and IL13RA1 in AT/RT ( Figure 2F and G) as well as SOX4 (which is consistent with a previous study) (27) , CCNG2 and STMN1 in MB ( Figure 2H -J), were also confirmed. Noted that genes involved in stem cell self-renewal and stemness, such as SOX1, S100A4, NOG and FGF2, were enriched in AT/RT (Supplementary Table 5 , available at Carcinogenesis Online). Because embryonic stemness genes are known to contribute in malignancy and patient prognosis (28) (29) (30) , our data suggest that AT/RT may possess more stem cell-like traits and is therefore more malignant.
When subjecting feature genes of AT/RT and MB into Gene Ontology database searches, we found that genes involved in accelerating cell proliferation (67 genes), wound healing (30 genes) and angiogenesis (22 genes) were overrepresented in AT/RT ( Figure 2K ). Other biological processes associated with AT/RT were the upregulation of genes involved in controlling cell migration (22 genes) and cellular component movement (23 genes) ( Figure 2K ). Conversely, the biological processes overrepresented in MB were those related specifically to nervous system development, including CNS development (24 genes) and axonogenesis (19 genes) and neurotransmitter secretion (9 genes) ( Figure 2L ). These results also suggest that MB is more differentiated than AT/RT.
miR-221/222 is an oncogenic miRNA cluster in embryonal tumors
According to smRNA-Seq and RT-qPCR data, we have found that miR-221-3p (formerly known as miR-221), miR-221-5p (miR-221*) and miR-222-3p (miR-222) are highly abundant in AT/RT but not in MB. These three miRNAs belong to the same miRNA cluster. The remainder of miR-221/222 cluster, the miR-222-5p (miR-222*), is also ranked among top 50 differentially expressed miRNAs between AT/RT and MB but with a lesser expression (Supplementary Figure 1 , available at Carcinogenesis Online). Thus we pondered if deregulated miR-221/222 expression might contribute to embryonal tumor malignancy.
To address this issue, the human MB cell line Daoy and the ATRT cell line CHLA-02-ATRT were stably transfected with the expression plasmid of miR-221/222 (Daoy-221/222 and CHLA-02-ATRT-221/222) or vector (Daoy-Vector and CHLA-02-ATRT-vector) and were detected for their cell proliferation rate. We found that cell overexpressing miR-221/222 had a faster growth rate than Vector control ( Figure 3A and Supplementary Figure 2A and B, available at Carcinogenesis Online). We also reduced miR-221/222 expression by antagomir in CHLA-02-ATRT cells and found that reducing miR-221/222 expression decreased cell proliferation ( Figure 3B ).To understand whether miR-221/222 may change tumor malignancy, we overexpressed miR-221/222 and evaluated tumor malignancy by in vitro anchorage-independent clonogenic assays and in vivo nude mice tumor growth assays. The colony forming ability of Daoy-221/222 in soft agar assay was markedly increased ( Figure 3C and Supplementary 2C, available at Carcinogenesis Online). And, by subcutaneous xenograft, Daoy-221/222 formed a larger tumor (226-and 246-fold by weight and volume, respectively) than Daoy-Vector in NOD/SCID mouse at day 88 post-implantation ( Figure 3D) .
We further introduced the expression of luciferase (Luc) into Daoy-221/222 and Daoy-Vector cells (Supplementary Figure 3A, available at Carcinogenesis Online). After injecting orthotopically these cells into the striatum of NOD/SCID mice followed by monitoring weekly by an IVIS (Supplementary Figure 3B, Figure 3E ). Final tumor sizes were confirmed ex vivo by 3D T2-weighted MRI (Supplementary Figure 4 , available at Carcinogenesis Online). Larger xenograft tumors in the brains injected with Daoy-221/222-Luc (23.4 ± 13.2 mm 3 ) than DaoyVector-Luc (9.5 ± 4.6 mm 3 ) were observed ( Figure 3F ). Collectively, these data point to miR-221/222 as an oncogenic miRNA cluster that not only uplifts cell proliferation but also promotes in vitro and in vivo tumorigenicity of embryonal tumor cells.
Global mRNA expression profiles of Daoy-221/222 and Daoy-Vector were also analyzed with microarray assays. When compared with DaoyVector, there were 1453 probe sets (1011 genes) upregulated and 1818 probe sets (1193 genes) downregulated in Daoy-221/222 (P < 0.05). MDS plot based on the expression of these probe sets showed that Daoy-221/222 is much closer to AT/RT than to Daoy-Vector ( Figure 3G ). These data suggest that deregulation of a single miRNA cluster, the miR-221/222, caused a dramatic change in transcriptome features of Daoy and make this MB cell line become AT/RT like and more aggressive.
Higher miR-221/222 and its associated lower SUN2 expression in AT/RT
A miRNA usually executes its functions through blocking the expression of target gene(s) at the post-transcriptional level. To investigate how miR-221/222 is involved in AT/RT pathogenesis, 1193 downregulated genes in Daoy-221/222 were used to compare with 440 downregulated genes in AT/RT (mentioned earlier in Figure 2 ) and 446 predicted miR-221/222 targets revealed by TargetScan ( Figure 4A ). Among all, 89 genes suppressed by overexpressing miR-221/222 in Daoy were also downregulated in AT/RT. Six of them (SUN2, SOX11, MEX3A, TCF4, SLC1A2 and USP47) were candidate direct targets of miR-221/222 in AT/RT ( Figure 4A ). The SUN2, a nuclear envelope protein in the LINC (linker of nucleoskeleton and cytoskeleton) complex, is of great interest to us because it has not been proposed any sort of a cancer-related function.
Suppressive SUN2 mRNA expression in AT/RT was confirmed by RT-qPCR. When compared with normal human cerebellum (fetal and adult), AT/RT appeared to possess a lower SUN2 level but MB did not ( Figure 4B ). The correlation coefficients (Pearson's r) between SUN2 and miR-221-3p as well as SUN2 and miR-222-3p were −0.777 and −0.802, indicating a negative correlation between SUN2 and miR-221/222 expression in AT/RT and MB ( Figure 4C and D) . These findings suggest that miR-221/222 may contribute to AT/RT malignancy by downregulating SUN2. Noted that the SUN2 expression is also associated with neural differentiation status; when compared with undifferentiated neural progenitor cells, SUN2 mRNA increased upon differentiation for 7 days ( Figure 4E ). These data were consistent with the previous inference that AT/RT possesses more stem cell-like traits than MB.
SUN2 is a direct downstream target of miR-221/222
To determine whether manipulating miR-221/222 expression influences SUN2 level in embryonal tumors, RT-qPCR and immunoblotting assays were performed to detect the transcript and protein of SUN2 in Daoy stably overexpressed miR-221 (Daoy-221), miR-222 (Daoy-222), miR-221/222 (Daoy-221/22) and vector ( Figure 4F and G). SUN2 transcript and protein were not suppressed in Daoy-221 or Daoy-222 but were reduced to 72% and 74%, respectively, in Daoy-221/222 compared with the control. We also overexpressed miR-221/222 in CHLA-02-ATRT cells, and SUN2 transcript and protein were decreased in CHLA-02-ATRT-221/222 cells (Supplementary Figure 5A , available at Carcinogenesis Online). These data suggest that miR-221/222 is more efficient than miR-221 or miR-222 alone in attenuating SUN2 expression.
The TargetScan indicates a potentially favorable interaction between miR-221-3p/miR-222-3p and one 8-mer site at the position 255-262 of SUN2 3′-untranslated region (3′UTR) (Figure 4H,  left) . By 3′UTR-Luc reporter assay, we found that both miR-221-3p and miR-222-3p could bind directly to the recognition element and reduce the activity of Luc fused to the full-length 3′UTR of SUN2 ( Figure 4H ). The suppressive effect of miR-222 (29.4%) was greater than that of miR-221 (19.6%), and miR-221/222 could reduce reporter activity even greater (37.1%). Mutating the predicted miR-221-3p/miR-222-3p recognition element in SUN2, 3′UTR restored mainly (but not completely) the miR-221-, miR-222-and miR-221/222-mediated suppression ( Figure 4H ). It is possible that other less conserved miR-221-3p/miR-222-3p recognition element(s) may exist. Nonetheless, these data support SUN2 as a direct target of miR-221/222.
SUN2 as a tumor suppressor mediates miR-221/222 functions in CNS embryonal tumors
To further characterize the role of SUN2 in embryonal tumors, clonal lines of Daoy and CHLA-02-ATRT with stable knockdown of endogenous SUN2 were created using two short hairpinproducing plasmids, shSUN2#A and #C, which targeted different regions of SUN2 ( Figure 5A and Supplementary Figure 5B , available at Carcinogenesis Online). Both shSUN2#A and shSUN2#C increased significantly adherent cell growth of Daoy and CHLA-02-ATRT ( Figure 5B and Supplementary Figure 5C , available at Carcinogenesis Online). The shSUN2#A, as a representative, elevated the clonogenicity of Daoy in soft agar assay ( Figure 5C and Supplementary Figure 5D , available at Carcinogenesis Online). To demonstrate whether overexpressing SUN2 could affect ATRT proliferation directly, we overexpressed SUN2 in CHLA-02-ATRT cells ( Figure 5D ) and evaluated the proliferation rate. We found that overexpression of SUN2 reduced cell proliferation ( Figure 5E ). These data suggest that SUN2 regulates cell proliferation and tumor malignancy in embryonal tumors.
Because we have demonstrated that SUN2 is a direct target of miR-221/222, we next wondered whether SUN2 downregulation is required for miR-221/222 to execute its oncogenic functions in embryonal tumors. As shown in Figure 5F , single overexpression of miR-221/222 elevated significantly cell proliferation of Daoy, whereas double overexpression of miR-221/222 and complete coding sequence of SUN2, which possesses no miR-221/222 recognition elements, counteracted the pro-proliferative effect. When subjecting the same batches of cells to soft agar assay, the clonogenicity of Daoy-221/222 was also attenuated significantly by overexpressing SUN2-CDS ( Figure 5G ). Thus, SUN2 downregulation is necessary for miR-221/222 to promote the proliferation and anchorage-independent growth of embryonal tumor cells in vitro.
To examine the tumor suppressive role of SUN2 in vivo, tumorigenicity assays using subcutaneous and orthotopic xenograft models of clonal Daoy with or without SUN2-knockdown were adopted. By subcutaneous xenograft, we observed more solid tumors and larger tumor size from Daoy-shSUN2#A (7 out of 7; 950 ± 533 mg and 926 ± 530 mm 3 ) than Daoy-shLacZ (1 out of 7; 0.4 ± 0.4 mg and 0.3 ± 0.3 mm 3 ) in NOD/SCID mice at day 154 post-injection ( Figure 5H) . By orthotopic xenograft, we detected more and more brilliant Luc bioluminescence from Daoy-shSUN2-Luc (up to 11.6 ± 4.8 × 10 7 photons/s), whereas undetectable to very low Luc bioluminescence from DaoyshLacZ-Luc (6.9 ± 2.3 × 10 4 photons/s) in mouse brains during the period of nine weeks ( Figure 5I and Supplementary Figure 6A and B, available at Carcinogenesis Online). Consistent with IVIS data, larger xenograft tumors from Daoy-shSUN2-Luc (20.3 ± 7.5 mm 3 ) than Daoy-shLacZ (0.9 ± 1.7 mm 3 ) were observed by 3D MRI ( Figure 5J and Supplementary Figure 7 , available at Carcinogenesis Online). Together these findings suggest that downregulating SUN2 alone is sufficient to promote in vitro and in vivo tumorigenesis of embryonal tumor cells.
Less SUN2 protein in AT/RT than MB by immunohistochemistry
To verify SUN2 protein expression in embryonal tumors, a largescale analysis of 187 formalin-fixed, paraffin-embedded tissues, including 33 AT/RTs and 154 MBs assembled in a tissue microarray format, was performed by immunohistochemistry (IHC) against SUN2. All samples were assessed for positive (++ or +) or negative (−) staining and for immunoreactive cell populations (%) by two neuropathologists (Figure 6 ). SUN2-immunoreactive cells exhibited distinct nuclear membrane positivity in both AT/RT and MB but with weaker immunoreactivity and lower cell population in AT/RT than in MB (P = 0.048 in chi-square test). Consistently, these data support a lower level of tumor-suppressive SUN2 protein in AT/RT.
Discussion
Using smRNA-Seq-based profiling and RT-qPCR, we have identified several miRNAs expressed differentially between AT/RT and MB ( Figure 1 and Supplementary Figure 1 , available at Carcinogenesis Online). Although it has been reported that miR-221 and miR-222 may serve as oncomiRs or anti-oncomiRs in various malignant cancers (16, 31, 32) , this is the first time the mechanism by which miR-221/222 plays its role in AT/RT is dissected. Determination of whether other deregulated miRNAs observed in this study are also fundamental to AT/RT tumorigenesis still awaits further studies. Because more and more deregulated miRNAs are found to play important roles in a variety of tumors, therapeutic potential of RNA medicine such as the application of antagomir or chemically modified miRNA is taking into greater consideration (33, 34) . Our data showed that anti-miR-221 and anti-miR-222 antagomirs could significantly reduce cell proliferation in AT/RT cell line. Notably, the use of antimiR-221 and anti-miR-222 antagomirs has been proved to reduce the growth of prostate carcinoma xenografts in mice and has long-lasting effects on miR-221 and miR-222 endogenous expressions (34) . Our findings thus suggest the therapeutic potential of anti-miR-221/222 therapy in AT/RT.
In this study, we also performed microarray-based transcriptome comparison to identify gene expression profiles unique to AT/ RT or MB. Cyclin D1, a target of INI1 protein whose overexpression has been detected with INI1 gene inactivation in AT/RT in previous studies (35) , showed 23.9-fold (q < 0.0001) and 26.8-fold (P = 0.002) higher expression in AT/RT than in MB by our microarray and RT-qPCR analyses, respectively (Supplementary Table 5 , available at Carcinogenesis Online and Figure 2C ). The higher expression of insulin-like growth factor 1 (3.0-fold, q < 0.0001) was also observed in AT/RT in our microarray data (Supplementary Table 5 , available at Carcinogenesis Online). These findings remain consistent in supporting a higher specific expression level of cyclin D1 and a reinforced insulin/insulin-like growth factor 1 autocrine/paracrine signaling in AT/RT (36) (37) (38) . Moreover, in our microarray and RTqPCR analyses, NOTCH2 showed 11.0-fold (q < 0.0001) and 9.0-fold (P = 0.002) as well as IL13RA1 showed 4.6-fold (q < 0.0001) and 2.7-fold (P = 0.005), respectively, higher expression in AT/RT than Table 5 , available at Carcinogenesis Online and Figure 2D and G). Site-specific delivery of anticancer agents to tumors represents recently a promising therapeutic strategy (39, 40) . Although further studies are needed, the high expression levels of these transmembrane proteins in AT/RT may suggest potential use of their ligands or antibodies for effectively guiding cytotoxic drug conjugates or sterically stabilized liposome-encapsulated drugs to tumor cells.
We found by MDS analysis that miR-221/222 changes the transcriptome features of MB cells and makes them more AT/RT like, at least at the gene expression level ( Figure 3G ). Genes such as KLHL9, SLC35B1 and HERPUD1 were affected and can be confirmed by RTqPCR (data not shown). Array data showed that miR-221/222 overexpression did not change the mRNA levels of known AT/RT markers such as INI1, GFAP, EMA, HFF-35 or Synatophysin(41), indicating miR-221/222 affect AT/RT malignancy via a novel mechanism. We proved here that Sun2 is one of the tumor suppressor targeted by miR-221/222. SUN2 is an inner nuclear membrane protein with an evolutionarily conserved Sad1/UNC-84 homology (SUN) domain at the C-terminus (42) . SUN2 is a part of the LINC complex, a proposed mechanical link tethering the nucleo-and cytoskeleton and, in this way, integrating both nuclear and cytoplasmic architecture via the nuclear envelope (43) . Other components in the LINC complex include emerin, lamin A/C, SUN1, nesprin-1 and nesprin-2. These components interact with each other at the nuclear envelope, with other associated proteins including actin and intermediate filaments and with chromatin (especially heterochromatic and centromeric DNA) (44, 45) . In addition to the mechanostructural functions of nuclear positioning and cellular rigidity, the LINC complex is also, while lesser known, involved in signaling pathways and gene regulation (45, 46) and is associated with human diseases such as EmeryDreifuss muscular dystrophy and Hutchinson-Gilford progeria syndrome (46, 47) . Importantly then, the role of LINC components in tumor etiology has not been reported. In this study, we provide the first evidence for a novel function of SUN2 as a tumor suppressor, which is regulated directly by the oncogenic miR-221/222 cluster in the mechanism underlying AT/RT tumorigenesis. We may suspect that the elevation of miR-221/222 as well as the diminution of SUN2 would lose the normal control of many other genes that burst simultaneously or sequentially into AT/RT tumor progression. Of note, a 3.5-fold (q < 0.0001) higher expression of Lamin A/C (LMNA) which encodes lamin A and lamin C, can also be observed in AT/RT than in MB according to our microarray data (Supplementary Table 5 , available at Carcinogenesis Online). Future studies for discovering the details of SUN2 (and maybe other LINC components) at the nuclear envelope in gene regulation and in regulation of the actin cytoskeleton that impact on mechnotransduction-related signal transmission in pediatric embryonal tumors are thus of great clinical necessity.
Supplementary material
Supplementary Tables 1-6 and Supplementary Figures 1-7 can be found at http://carcin.oxfordjournals.org/ 
